Leucine
CAS 61-90-5
Leucine (CAS 61-90-5) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 8 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | MIC | 5936.153846153846 nM | 13 | - |
| - | IC50 | 32421.802857142855 nM | 6 | - |
| - | Kd | 20 nM | 1 | - |
| Large neutral amino acids transporter small subunit 1 Transporter |
IC50 | 4.07 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Foetal growth restriction | 15 | 67.383 | 10070531 |
| Device related sepsis | 10 | 48.145 | 10069802 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Leucine | 6308 | SU | MTHSPL |
| LEUCINE | 6308 | SU | MTHSPL |
| leucine | 6308 | IN | RXNORM |
| L-leucine | 6308 | SY | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Leucine used for in pharmaceutical contexts?
Leucine (CAS 61-90-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Leucine?
Leucine has 8 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Foetal growth restriction, Device related sepsis, Dehydration, Neurotoxicity, Renal impairment. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Leucine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for L-Leucine with EU status "permitted".
What clinical phase is Leucine in?
Leucine is rendered with ChEMBL max phase 3.
What bioactivity targets are documented for Leucine?
Leucine has 4 bioactivity rows in this page query. Rendered target entries include Large neutral amino acids transporter small subunit 1.